MRK Stock Merck & Company Inc - Complete Overview

Nyse / Pharmaceutical Products / Healthcare / MRK Stock

Merck & Company Inc (MRK) price per share as of 13 Jul 2018
Your sentiment
Shares Outstanding 2.69B
Avg Daily Volume 10.36M
Market Cap 152.7B
Volatility 20.34% MEDIUM


MRK stock is a pharmaceutical products company traded on Nyse. It is valued at 152.7B US dollars. There are 2.69B shares outstanding which Merck & Company Inc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 20.34% stock on average. Merck & Company Inc is paying dividends with the latest yield of 3.30%. It brought investors a total return of 4.60% over the last 12 months. Merck & Company Inc stock is relatively expensive. It's P/E ratio is above the market average.



Earnings Per Share 0.58
Dividends Per Share 1.90
12 Months Price Performance Low
Dividend Yield Low
Total Return Low


Pfizer shares rise after President Trump attacks its drug price hikes

President Donald Trump criticized pharmaceutical giant Pfizer Inc. in a Monday tweet for recently increasing the prices of many of its prescription drugs. In the tweet, which referred to Pfizer and unspecified "others," Trump said that companies were "merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!" Pfizer shares rose 0.5% in heavy early afternoon trade. The presidential tweet follows a Financial Times report that Pfizer raised list prices for 100 products in early July, weeks after Trump promised large price reductions, and marking the second such increase this year for Pfizer. The drugmaker also decreased the prices of five products, according to the report. Pfizer told the Financial Times that the increases, which were made on the drugs' so-called "list prices," did not reflect net price increases, estimated to be in the low single digits. Drug companies tend to increase the prices of their drugs early in the year and then again in the summer, and Pfizer was one of several to do so this month. Trump previously attacked pharmaceutical company Merck & Co. Inc. and its "ripoff drug prices" after Chief Executive Kenneth Frazier left a presidential advisory council in light of a white-supremacist rally in Charlottesville, Va. Pfizer shares have surged 5.2% over the last three months, compared with a 6.4% rise in the S&P 500 and a 3.2% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Roche Makes Claim To Another Win In The Front-Line Cancer Setting

Roche reveals that TECENTRIQ in combination with Celgene's Abraxane improves progression-free survival in patients with front-line metastatic triple-negative breast cancer.Full clinical data from the

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

Which of these cancer-focused biotech stocks is the better pick right now?

3 Best Big Pharma Stocks of 2018 So Far

Are any of these biggest year-to-date winners smart picks for the long term?

3 Things In Biotech, June 25: Bad News For Checkpoints In Bladder. Good News In Liver!

The FDA drops the hammer (just a bit!) on Roche and Merck.Lilly digs in its heels in liver cancer.Adamas keeps the lid on Parkinson's disease.

TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche

Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.


Name Value Action
RSI(14) 64.71 Strong buy
CMO(14) 29.43 Strong buy
ADX(14) 20.65 Buy
Williams %R -4.63 Sell


MRK Industry Sector Market
Price to Earnings 97.86 58.99 86.82 29.24
Price to Book Value 4.54 4.24 4.45 3.48
Price to Sales 3.75 3.40 4.04 3.26
Return on Equity 4.30% 14.07% 14.08% 15.51%
Return on Assets 1.80% 6.17% 6.88% 5.81%
All values TTM (trailing twelve months). Source: